mRNA HIV vaccine edges closer amid funding headwinds
An African-led effort to develop an mRNA–based HIV vaccine argues the platform can rapidly iterate toward a vaccine that teaches the immune system to neutralize diverse HIV strains. Yet the field faces a funding and political setback after the US government cut HIV-related support, risking halted trials and stalled collaboration. While early data and monkeys show promise and lower-dose safety improvements are being explored, sustained funding and political backing remain crucial to translating scientific momentum into a working vaccine.